The Translational Genomics Research Institute (TGen) has discovered potential drug targets to reduce pain in pancreatic cancer patients.
TGen researchers have found that nerve growth factor (NGF), a neurotrophic factor, and its receptor TRKA are associated with perineural invasion (PNI), which is the ability of pancreatic cancer cells to invade surrounding nerves. Read more . . .